← All organizations

Satsuma Pharmaceuticals, Inc.

For profitWebsite ↗

Also known as: Satsuma Pharmaceuticals, Inc. | SATSUMA PHARMS

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

Last known activity

Jun 30, 2021

Acquired by Shin Nippon Biomedical Laboratories on Apr 16, 2023

Timeline

2010s

Jan 1, 2016
Satsuma Pharmaceuticals, Inc.— Founded

2020s

Apr 16, 2023
Shin Nippon Biomedical Laboratories— Acquired By
Apr 30, 2025
dihydroergotamine— Marketing Organization

Drugs by trial phase (1 distinct, 5 trials)

Phase 3 (1 own, 0 via acquisition)

dihydroergotamine

Indications

Studied for

Marketed drugs (1)

dihydroergotamine

Recent trials (8)

NCT04940390Lead sponsorPhase 3Jun 30, 2021
NCT04940390Study chairPhase 3Jun 30, 2021
NCT05337254Lead sponsorPhase 1Mar 5, 2021
NCT04406649Study chairPhase 3Aug 31, 2020
NCT04406649Lead sponsorPhase 3Aug 31, 2020
NCT03901482Study chairPhase 3Jun 24, 2019
NCT03901482Lead sponsorPhase 3Jun 24, 2019
NCT03874832Lead sponsorPhase 1Sep 11, 2018

Details

Founded: San Francisco, CA, US Jan 1, 2016
Last known activity: Jun 30, 2021